Clinical Report: Link Between Polymorphisms in the MAP2 Gene and Schizophrenia Risk

Overview

This study identifies multiple single nucleotide polymorphisms (SNPs) in the MAP2 gene associated with increased schizophrenia risk in a Han Chinese cohort.

Background

Schizophrenia is a highly heritable disorder affecting approximately 1% of the global population, with significant genetic contributions to its etiology. The MAP2 gene plays a crucial role in neuronal structure and function, making it a candidate for understanding genetic risk factors in schizophrenia. Investigating genetic variations in MAP2 may provide insights into the biological mechanisms underlying the disorder.

Data Highlights

Key Findings

• Multiple MAP2 SNPs were identified as associated with schizophrenia risk.
• The AA genotype of rs288057 and the GG genotype of rs288087 were significantly linked to increased disease risk.
• Patients exhibited lower MAP2 mRNA levels compared to healthy controls, with genotype-dependent expression.
• MAP2 expression correlated positively with the severity of negative symptoms as measured by SANS scores.
• ROC analysis indicated MAP2 expression levels could distinguish patients from controls with an AUC of 0.728.

Clinical Implications

The findings indicate that genetic variations in the MAP2 gene may influence schizophrenia risk and symptom severity.

Conclusion

This study identifies MAP2 as a schizophrenia risk gene, linking genetic variations to reduced expression and negative symptomatology.

Related Resources & Content

1. Frontiers | Association of MAP2 gene polymorphisms and altered expression with schizophrenia risk in a Chinese Han population
2. Pediatric Cardiology — Genetic Variants in BMP4 Linked to Increased Risk of Sporadic Congenital Heart Disease in Han Chinese Individuals
3. Clinical Rheumatology — Link Between the T Allele of rs2431697 at 5q33.3 and Systemic Lupus Erythematosus: A Case-Control Investigation and Meta-Analysis
4. Acta Neuropathologica — Comprehensive Analysis of Pathway-Specific Polygenic Risk and Transcriptomic Networks Reveals New Functional Pathways in Parkinson's Disease
5. Blood Cancer Journal — Exploring Modifiable Risk Factors for Clonal Haematopoiesis Development Through Mendelian Randomisation
6. Die neue S3-Leitlinie Schizophrenie (living) 2025 | Der Nervenarzt | Springer Nature Link
7. VA/DoD Clinical Practice Guideline for Management of First-Episode Psychosis and Schizophrenia
8. Whole-exome sequencing analysis identifies risk genes for schizophrenia | Nature Communications
9. Dang 2025: Schizophrenia GWAS Mixed Ancestry | Knowledge Portal Network
10. A review of post-GWAS studies in schizophrenia | Translational Psychiatry
11. Low Stability and Specificity of Polygenic Risk Scores for Major Psychiatric Disorders Limit their Clinical Utility - PMC
12. Clinical use of polygenic risk scores: current status, barriers and future directions | Nature Reviews Genetics
13. Frontiers | Association of MAP2 gene polymorphisms and altered expression with schizophrenia risk in a Chinese Han population
14. Deciphering the alteration of MAP2 interactome caused by a schizophrenia-associated phosphorylation - ScienceDirect